drugset / Trial / NCT03079219
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The Olanzapine Regimen will be superior to the Standard Regimen, as measured by the proportion of patients with Complete Response in the 120 hours following AC chemotherapy.
Timeline
- Start
- 2017-03-23
- Primary completion
- 2021-03-01
- Completion
- 2021-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 4 mg | — |
| Subject | Dexamethasone | Small molecule | 12 mg | — |
| Subject | Olanzapine | Small molecule | 10 mg | — |
| Background | Aprepitant | Other / unclassified | 80 mg | — |
| Background | Ondansetron | Other / unclassified | 8 mg | — |